Hemab Therapeutics Holdings Inc. (COAG:NASDAQ) closed at $29.56 on October 14, 2026, down 0.81% on the day. The stock trades 46.7% below its 52-week high of $55.42 and 28.5% above its 52-week low of $23.00. Over the past year, it lost 12.4%. Hemab Therapeutics Holdings Inc. is part of the Health Care sector.
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -5.76% | -26.37% | -33.08% | -12.35% | -12.35% |
In 113 trading sessions since May 4, 2026, COAG closed higher on 58 days (51%). Its best day was June 26, 2026 (+16.77%) and its worst was May 4, 2026 (-25.47%). The stock moved 10% or more in a single session 8 times.
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Hemab's mission is to discover, develop, and commercialize innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Hemab is building a franchise of innovative therapeutics designed to address critical gaps in the treatment of coagulation disorders, including sutacimig (HMB-001), a bispecific antibody in clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency, and HMB-002, a monovalent antibody in clinical development for the prophylactic treatment of Von Willebrand Disease.
Find more stocks like COAG with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.